FDA accepts Milestone's response on Cardamyst nasal spray, sets new PDUFA date; company raises $52.5 million to support ...

Today’s health headlines: ketamine nasal sprays offer a new option for people with treatment-resistant depression. Plus, how ...

People with hay fever could one day benefit from a first-of-its-kind “molecular shield” that blocks pollen from entering the ...

The Food and Drug Administration (FDA) has accepted for review Milestone’s response to issues raised in a Complete Response Letter (CRL) for etripamil nasal spray (Cardamyst ™ ), an investigational ...

A new study shows that oxytocin nasal spray helps mothers with postpartum depression interact more positively with their babies.

A mid-stage trial of BPL‑003 nasal spray shows promising results for treatment-resistant depression, igniting biotech ...

Vaccine experts have developed an antibody that, when applied to the nose, intercepts allergens before they can trigger a ...

New PDUFA Action Date of December 13, 2025 $75 Million Royalty Purchase Agreement Payment from RTW Extended Through 2025 MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® ...

ARS Pharmaceuticals' Neffy, an epinephrine nasal spray, is poised as a game-changer for emergency allergies, driving growth.

Can nasal polyps be removed without surgery, and will they come back? Learn about your treatment options and success rates, including nasal sprays, oral medications, nasal polyp suction, and ...

A psychedelic nasal spray requiring a much shorter period of clinical supervision has shown promise against ...